TR201910572T4 - Anti-cd26 antikorları ve bunların kullanımları. - Google Patents

Anti-cd26 antikorları ve bunların kullanımları. Download PDF

Info

Publication number
TR201910572T4
TR201910572T4 TR2019/10572T TR201910572T TR201910572T4 TR 201910572 T4 TR201910572 T4 TR 201910572T4 TR 2019/10572 T TR2019/10572 T TR 2019/10572T TR 201910572 T TR201910572 T TR 201910572T TR 201910572 T4 TR201910572 T4 TR 201910572T4
Authority
TR
Turkey
Prior art keywords
present
moreover
treatment
antibodies
provides
Prior art date
Application number
TR2019/10572T
Other languages
English (en)
Inventor
Francesco Di Naro Antonio
Original Assignee
Adienne S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48092884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201910572(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adienne S A filed Critical Adienne S A
Publication of TR201910572T4 publication Critical patent/TR201910572T4/tr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)

Abstract

Mevcut buluş, CD26'ya bağlanabilen yeni antikorlar, ve bir ilaç olarak kullanımları ile ilgilidir. Dahası, mevcut buluş, Graft-versus-Host Hastalığının (GvHD) tedavisinde ve/veya önlenmesinde kullanıma yönelik, Aplastik Aneminin tedavisinde kullanıma yönelik ve/veya hematopoietik kök hücre transplantasyonundan sonra aşılamanın arttırılmasında kullanıma yönelik antikorları sağlamaktadır. Dahası, mevcut buluş, mevcut buluşun en az bir antikoru içeren, farmasötik bileşimleri sağlamaktadır, ayrıca parçaların bir kitini sağlamaktadır.
TR2019/10572T 2013-02-19 2014-02-19 Anti-cd26 antikorları ve bunların kullanımları. TR201910572T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13425029.9A EP2767549A1 (en) 2013-02-19 2013-02-19 Anti-CD26 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
TR201910572T4 true TR201910572T4 (tr) 2019-08-21

Family

ID=48092884

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/10572T TR201910572T4 (tr) 2013-02-19 2014-02-19 Anti-cd26 antikorları ve bunların kullanımları.

Country Status (26)

Country Link
US (2) US9376498B2 (tr)
EP (3) EP2767549A1 (tr)
JP (2) JP6240195B2 (tr)
KR (1) KR101869589B1 (tr)
CN (1) CN104684931B (tr)
AU (1) AU2014220777B2 (tr)
CA (1) CA2874422C (tr)
CY (1) CY1121980T1 (tr)
DK (1) DK2864359T3 (tr)
ES (1) ES2738283T3 (tr)
HK (1) HK1205151A1 (tr)
HR (1) HRP20191277T8 (tr)
HU (1) HUE045150T2 (tr)
IL (1) IL237244B (tr)
LT (1) LT2864359T (tr)
ME (1) ME03753B (tr)
MX (1) MX357293B (tr)
NZ (1) NZ631111A (tr)
PL (1) PL2864359T3 (tr)
PT (1) PT2864359T (tr)
RS (1) RS59093B1 (tr)
RU (1) RU2662933C2 (tr)
SA (1) SA515360248B1 (tr)
SI (1) SI2864359T1 (tr)
TR (1) TR201910572T4 (tr)
WO (1) WO2014128168A1 (tr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11242399B2 (en) * 2013-02-19 2022-02-08 Adienne S.A. Anti-CD26 antibodies
EP2767549A1 (en) * 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof
US10630229B2 (en) * 2016-10-11 2020-04-21 Kevin Stapleton Panel mounting bracket with grounding mid-clamp and related methods
KR101960414B1 (ko) * 2016-11-11 2019-03-27 대한민국 사람 유래 dpp-4 유전자를 이용한 당뇨 질환 모델용 형질전환돼지 및 이의 용도
MX2020006488A (es) * 2017-12-22 2020-12-10 Adienne S A Metodo celular cuantitativo para determinar la actividad biologica de un ligando anti-cd26.
CN109709337B (zh) * 2018-12-28 2021-09-14 江苏众红生物工程创药研究院有限公司 人cd26的免疫组化检测试剂盒及其临床应用
CN117120475A (zh) * 2020-07-28 2023-11-24 阿迪安股份公司 特发性炎性肌病的治疗
WO2022238977A2 (en) 2021-05-13 2022-11-17 Adienne S.A. Methods of treating dermatomyositis
WO2022238978A1 (en) 2021-05-13 2022-11-17 Adienne S.A. Methods of treating graft versus host disease
CN118359716A (zh) * 2023-01-18 2024-07-19 江苏众红生物工程创药研究院有限公司 抗cd26抗体及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
NL9400309A (nl) * 1993-11-04 1995-06-01 Eurogenetics Nv Ligande die in staat is te binden aan de adenosine deaminase bindingsplaats van CD26.
PT1241179E (pt) 1998-04-15 2006-12-29 Genentech Inc Proteína humana possuindo actividade antiproliferativa in vitro
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
WO2002092127A1 (en) * 2001-05-11 2002-11-21 Board Of Regents, The University Of Texas System Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
PL1844337T3 (pl) 2005-01-24 2013-12-31 Pepscan Systems Bv Związki wiążące, związki immunogenne i peptydomimetyki
BRPI0607486B8 (pt) 2005-03-03 2021-05-25 Immunomedics Inc anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.
CN101282994B (zh) * 2005-07-22 2013-09-18 Y's治疗有限公司 抗cd26抗体及其使用方法
EA015735B1 (ru) * 2005-09-14 2011-10-31 Такеда Фармасьютикал Компани Лимитед Фармацевтические композиции на основе 2-[[6-[(3r)-3-амино-1-пиперидинил]-3,4-дигидро-3-метил-2,4-диоксо-1(2н)-пиримидинил]метил]бензонитрила
US8846393B2 (en) * 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
RU2331881C1 (ru) * 2007-03-09 2008-08-20 ГОУ ВПО "Красноярская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" Способ определения риска развития атопических заболеваний у новорожденных детей
CA2738485A1 (en) 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
AU2011291651B2 (en) * 2010-08-18 2016-01-14 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
EP2767549A1 (en) * 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof

Also Published As

Publication number Publication date
WO2014128168A1 (en) 2014-08-28
JP2015529204A (ja) 2015-10-05
RU2014153440A (ru) 2016-07-20
KR101869589B1 (ko) 2018-06-20
SI2864359T1 (sl) 2019-09-30
US20160264676A1 (en) 2016-09-15
IL237244B (en) 2019-09-26
NZ631111A (en) 2017-06-30
SA515360248B1 (ar) 2017-02-20
RU2662933C2 (ru) 2018-07-31
EP2767549A1 (en) 2014-08-20
CN104684931B (zh) 2019-08-27
JP2017221205A (ja) 2017-12-21
EP3536711A1 (en) 2019-09-11
AU2014220777A1 (en) 2014-11-27
HRP20191277T1 (hr) 2019-10-18
HK1205151A1 (en) 2015-12-11
US10208126B2 (en) 2019-02-19
JP6240195B2 (ja) 2017-11-29
HUE045150T2 (hu) 2019-12-30
EP2864359B1 (en) 2019-04-24
CN104684931A (zh) 2015-06-03
CA2874422C (en) 2021-10-19
RS59093B1 (sr) 2019-09-30
AU2014220777B2 (en) 2017-03-16
PL2864359T3 (pl) 2019-11-29
LT2864359T (lt) 2019-09-25
ES2738283T3 (es) 2020-01-21
CY1121980T1 (el) 2020-10-14
CA2874422A1 (en) 2014-08-28
KR20150023419A (ko) 2015-03-05
HRP20191277T8 (hr) 2019-11-01
MX357293B (es) 2018-07-04
US9376498B2 (en) 2016-06-28
US20150017178A1 (en) 2015-01-15
DK2864359T3 (da) 2019-07-22
EP2864359A1 (en) 2015-04-29
BR112015002130A2 (pt) 2017-11-07
PT2864359T (pt) 2019-07-26
IL237244A0 (en) 2015-04-30
MX2014014935A (es) 2015-06-17
ME03753B (me) 2021-04-20

Similar Documents

Publication Publication Date Title
TR201910572T4 (tr) Anti-cd26 antikorları ve bunların kullanımları.
CL2018000106A1 (es) Moléculas de anticuerpo que se unen a cd45
EA201400579A1 (ru) Антитела к il-36r
TR201910103T4 (tr) Anti-fcrn antikorları.
UA117072C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини, і cd3, що не є людським
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
EA201290590A1 (ru) Модифицированные туберкулезные антигены
EA201370018A1 (ru) Составы рифаксимина и их применение
EA202193044A2 (ru) Способы лечения таупатии
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201390993A1 (ru) Антитела к cd38
EA201401204A1 (ru) Антитела к il-23p19
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
MA37538A2 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
TR201910744T4 (tr) Büyüme ve farklılaşma faktörü 15 e (gdf-15) yönelik monoklonal antikorlar.
EA201390660A1 (ru) Модифицированные никотиновые соединения и связанные способы
CL2015001472A1 (es) Composiciones y métodos para anticuerpos dirigidos epo.
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
NZ606988A (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
EA201590491A1 (ru) Иммуногенная композиция
UA111340C2 (uk) Антитіло, яке специфічно зв'язується з tnf-альфа людини
PE20160528A1 (es) Anticuerpos
CL2012003458A1 (es) Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico.
EA201390467A1 (ru) Композиции антител и способы применения
EA201690992A1 (ru) Антитела, специфичные к fcrn